Product
Iadademstat
Aliases
ORY 1001, ORY-1001, ORY-1001, RO7051790, RG6016 (4 other aliases)
4 clinical trials
7 indications
Indication
Acute Myeloid LeukemiaIndication
RelapseIndication
Small Cell Lung CancerIndication
Neuroendocrine CarcinomaIndication
Extensive-stage small cell lung cancerIndication
Stage IV Lung CancerClinical trial
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical TrialStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination With Azacitidine and Venetoclax in Newly Diagnosed AMLStatus: Not yet recruiting, Estimated PCD: 2026-03-08
Clinical trial
A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine CarcinomasStatus: Recruiting, Estimated PCD: 2025-08-05
Clinical trial
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2026-01-31